XVIPF (Xvivo Perfusion AB) Cyclically Adjusted Revenue per Share: $1.46 (As of Mar. 2026)


XVIPF Xvivo Perfusion AB XVIPF
91 GF Score
Price $29.00
GF Value $42.07
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Xvivo Perfusion AB Cyclically Adjusted Revenue per Share?

Xvivo Perfusion AB XVIPF -1.32% 91 Cyclically Adjusted Revenue per Share is $1.46 as of Mar. 2026. GuruFocus rates XVIPF with a GF Score™ of 91/100 and a GF Value™ of $42.07 (Significantly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Xvivo Perfusion AB's adjusted revenue per share for the three months ended in Mar. 2026 was $0.820. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $1.46 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Xvivo Perfusion AB's average Cyclically Adjusted Revenue Growth Rate was 15.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 19.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Xvivo Perfusion AB was 19.90% per year. The lowest was 19.90% per year. And the median was 19.90% per year.

As of today (2026-06-26), Xvivo Perfusion AB's current stock price is $29.0011. Xvivo Perfusion AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $1.46. Xvivo Perfusion AB's Cyclically Adjusted PS Ratio of today is 19.86.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Xvivo Perfusion AB was 48.21. The lowest was 12.05. And the median was 27.44.


Xvivo Perfusion AB  (OTCPK:XVIPF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Xvivo Perfusion AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=29.0011/1.46
=19.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Xvivo Perfusion AB was 48.21. The lowest was 12.05. And the median was 27.44.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Xvivo Perfusion AB Cyclically Adjusted Revenue per Share Related Terms


Xvivo Perfusion AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Xvivo Perfusion AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xvivo Perfusion AB Cyclically Adjusted Revenue per Share Chart

Xvivo Perfusion AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.92 0.70 1.03 1.57

Xvivo Perfusion AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.36 1.40 1.50 1.57 1.46

XVIPF vs ABT, SYK, MDT: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Xvivo Perfusion AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xvivo Perfusion AB Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Xvivo Perfusion AB's Cyclically Adjusted PS Ratio falls into.


XVIPF
91GF Score
Xvivo Perfusion AB XVIPF
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xvivo Perfusion AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Xvivo Perfusion AB's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.82/133.3862*133.3862
=0.820

Current CPI (Mar. 2026) = 133.3862.

Xvivo Perfusion AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.193 101.019 0.255
201609 0.156 101.138 0.206
201612 0.179 102.022 0.234
201703 0.176 102.022 0.230
201706 0.163 102.752 0.212
201709 0.153 103.279 0.198
201712 0.188 103.793 0.242
201803 0.197 103.962 0.253
201806 0.199 104.875 0.253
201809 0.171 105.679 0.216
201812 0.245 105.912 0.309
201903 0.192 105.886 0.242
201906 0.223 106.742 0.279
201909 0.208 107.214 0.259
201912 0.248 107.766 0.307
202003 0.177 106.563 0.222
202006 0.123 107.498 0.153
202009 0.167 107.635 0.207
202012 0.251 108.296 0.309
202103 0.232 108.360 0.286
202106 0.243 108.928 0.298
202109 0.218 110.338 0.264
202112 0.323 112.486 0.383
202203 0.324 114.825 0.376
202206 0.318 118.384 0.358
202209 0.301 122.296 0.328
202212 0.428 126.365 0.452
202303 0.450 127.042 0.472
202306 0.480 129.407 0.495
202309 0.439 130.224 0.450
202312 0.482 131.912 0.487
202403 0.567 132.205 0.572
202406 0.634 132.716 0.637
202409 0.612 132.304 0.617
202412 0.655 132.987 0.657
202503 0.682 132.825 0.685
202506 0.592 133.699 0.591
202509 0.639 133.482 0.639
202512 0.771 133.386 0.771
202603 0.820 133.386 0.820

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $1.46 mean?
Xvivo Perfusion AB (XVIPF) has a Cyclically Adjusted Revenue per Share of $1.46 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Xvivo Perfusion AB and its competitors.
Is Xvivo Perfusion AB's Cyclically Adjusted Revenue per Share too high?
Xvivo Perfusion AB's current Cyclically Adjusted Revenue per Share is $1.46. Overall, Xvivo Perfusion AB has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Cyclically Adjusted Revenue per Share compare to ABT and SYK?
Xvivo Perfusion AB's Cyclically Adjusted Revenue per Share of $1.46 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Xvivo Perfusion AB and its competitors. Xvivo Perfusion AB's current Cyclically Adjusted Revenue per Share is $1.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $42.07, compared to a current price of $29.00 — trading 31.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $1.46. Xvivo Perfusion AB's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current Cyclically Adjusted Revenue per Share is $1.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?

Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued. The current stock price of $29.00 is trading 31.1% below its estimated GF Value™ of $42.07. GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.

Key valuation signals for XVIPF:

  • Cyclically Adjusted Revenue per Share: $1.46
  • GF Value™: $42.07 vs. price of $29.00 (31.1% below fair value)
  • GF Score™: 91/100 with 2 warning signs

No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Xvivo Perfusion AB Business Description

Address Gemenskapens gata 9, Molndal, SWE, SE-431 53
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
91GF Score

Get the complete analysis for XVIPF

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.00
Price
$42.07
GF Value